El estudio Solidarity, coordinado por la Organización Mundial de la Salud en más de 30 países, indica que las terapias con remdesivir, hidroxicloroquina, lopinavir/ritonavir e interferón no han te...
Read moreThe sophisticated human immune system has evolved to become an effective protection system against a great number of diseases, cancer being one of them. The immune system recognises and destroys cance...
Read moreWith the participation of the Breast Unit of the Arnau de Vilanova University Hospital and IRBLleida
Read moreThe Catalan biopharmaceutical company AbilityPharma, focused on the development of innovative oral anticancer compounds, undertakes the last stage of the investment round with which this year it will ...
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported ...
Read more3P Biopharmaceuticals, compañía biotecnológica CDMO especializada en el desarrollo de procesos y fabricación bajo normas de correcta fabricación (cGMPs) de medicamentos biológicos y productos de...
Read moreMinoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating treatment options in orphan central nervous system (CNS) disorders, today announces that th...
Read morePivotal announced today that it has been contracted by Checkpoint Therapeutics Inc., a New York City-based biotechnology company, to provide expert clinical research services in Europe for its upco...
Read moreOncoheroes today announced its organizational membership into the Coalition Against Childhood Cancer, known as CAC2, a collaborative network of organizations and individuals supporting and servicing t...
Read moreThe R&D team at Intas has developed a COVID-19 specific Hyperimmune Globulin as treatment for patients suffering from moderate to severe COVID-19infection. Hyperimmune Globulin also has potential for ...
Read moreResearchers and clinicians can use the database to further the development of new types of antibiotics.
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today...
Read more